Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc) Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading
Enlight Renewable Energy Ltd: Revenues from sales of electricity in 2017 met expectations; full commercial operation in Ireland; a growing project pipeline; stock target price remains at 2.30. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading
DNA Biomedical Solutions Ltd.: Preparations for pre-IND (505(b) (2) submission and expected capital raising by Entera; BeamMed retains a similar sales rate with a growing presence in the US; Target price remains unchanged. jaimeuss_admin 30 בAugust 2018 Research 0 Comments Continue Reading
Safe-T: Company’s 2017 financial results are in line with our expectations; stock target price unchanged at NIS 9.38 jaimeuss_admin 30 בAugust 2018 Research 0 Comments Continue Reading
Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018; Mild setback in FDA marketing approval (OCD); Price target remains within the forecast range. jaimeuss_admin 30 בAugust 2018 Research 0 Comments Continue Reading